Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349410 · ClinicalTrials.gov registry record · Phase 2
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
A Phase 2 study, sponsored by The Camelot Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,800
- Enrollment target
NCT04349410 is a Phase 2 study that has completed, run by The Camelot Foundation. The registered enrollment target is 1,800 participants.
The verdict
NCT04349410, a Phase 2 study, has completed, sponsored by The Camelot Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,800 participants
- Enrollment target
Study Summary
Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons \[1\] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.
Interventions
- DRUG Hydroxychloroquine, Azithromycin
- DRUG Hydroxychloroquine, Doxycycline
- DRUG Hydroxychloroquine, Clindamycin
- DRUG Hydroxychloroquine, Clindamycin, Primaquine - low dose.
- DRUG Hydroxychloroquine, Clindamycin, Primaquine - high dose.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2020-04-11 |
| Est. Completion | 2020-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04349410
The ClinicalTrials.gov registry entry for NCT04349410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Camelot Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Hydroxychloroquine, Azithromycin is the first listed.
NCT04349410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04349410 about?
NCT04349410 is a clinical study titled "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol". Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of re...
What is the current status of trial NCT04349410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,800 participants. The study started on 2020-04-11. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT04349410?
The interventions under investigation include: Hydroxychloroquine, Azithromycin (DRUG), Hydroxychloroquine, Doxycycline (DRUG), Hydroxychloroquine, Clindamycin (DRUG), Hydroxychloroquine, Clindamycin, Primaquine - low dose. (DRUG), Hydroxychloroquine, Clindamycin, Primaquine - high dose. (DRUG).
Who is sponsoring clinical trial NCT04349410?
This trial is sponsored by The Camelot Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.